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Abstract
Attention deficit hyperactivity disorder (ADHD) is a psychopathology commonly
characterized by general inattentiveness and/or a lack of impulse control resulting in
hyperactive tendencies. ADHD is estimated to cost the United States roughly $266 billion
every year. ADHD is currently treated via medications, cognitive behavioral therapy, or
more recently, neurofeedback. Neurofeedback – and biofeedback in general – is the
process of providing a patient with information about autonomic bodily functions so that
they may control said autonomic function. In the case of ADHD, neurofeedback focuses
on reinforcing the behaviors and sensations associated with attentiveness. Currently
however, neurofeedback systems are large and require a patient to travel to a clinic.
Furthermore, the current offering of portable neuro/biofeedback devices do not have the
technological capabilities to provide effective neurofeedback therapy. Current wearable
tech devices – such as the Apple Watch and Samsung Gear – possess the technological
capabilities to measure important bodily functions, and provide appropriate biofeedback
therapy while remaining discrete and most importantly, portable.
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Introduction
Attention deficit hyperactivity disorder (ADHD) is a psychopathology commonly
characterized by general inattentiveness and/or a lack of impulse control resulting in
hyperactive tendencies (Barkley, 2015). Associated with symptoms like daydreaming,
forgetting, fidgeting, and squirming, ADHD can greatly interfere with a child’s learning
as well as an adult’s productivity in the workplace. These behaviors have serious
economic consequences: ADHD is estimated to cost the United States roughly $266
billion every year, 70% of which can be accounted towards loss of income and loss of
work productivity for adults with ADHD (Doshi, 2012).
In the United States, 11% of children ages 4 – 17 and 4.4% of adults have been
diagnosed with ADHD (Pastor, 2015). These numbers have been steadily increasing
since the 1970s, due in part to changes in diagnostic criteria and to an increased
availability and acceptance of treatment through medication (Barkley, 2010). Of the
aforementioned $266 billion cost associated with ADHD, 10% arises from special
services ranging from educational accommodations to visits to the physician, whereas
20% goes towards paying for medication (Doshi, 2012).
The costs of medication and associated services to treat ADHD can be particularly
significant in the United States, due to the expectation that patients will shoulder the costs
of health care. According to Doshi (2012), the average American is estimated to spend
$1,105 out of pocket on pharmaceuticals and medical goods. This cost represents over
155% more than the combined average of all other nations in the data group. For ADHD,
the breakdown per year on an individual level is estimated to include education costs of
roughly $3,000 per person in a family, and medication and healthcare costs of roughly
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$2,500 per person in a family. My personal experience as an individual with ADHD is
illustrative of how quickly costs can increase. Every three months, I must pay $650 for a
bottle of 90 pills. Every time I am prescribed these pills, I must go into my physician’s
office for a check-up, bringing the real cost of my prescription up to $1,250. In total per
year, I spend $5000 on medication alone.
However, as the number of ADHD diagnoses continues to increase, concerns
about the over-prescription of ADHD medication have been rising (National Institute on
Drug Abuse, 2016). Typical medications for ADHD are stimulants that act on
neurotransmitters in the central nervous system. Along with their high economic costs,
the effects of prolonged use of these substances is unclear, especially for individuals with
less severe symptoms and/or ongoing neurodevelopment (National Institute on Drug
Abuse, 2016). For this reason, the American Psychological Association (APA) and
Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD) have
identified a general desire and potential need to avoid prescribing drugs, especially to
younger children. Together, the two organizations have conducted a series of studies
identifying effective treatments for ADHD.
According to research by these organizations, cognitive behavioral therapy (CBT)
is an effective alternative to medication in both individual and group settings (Barkley,
2010). However, the effectiveness of CBT is potentially limited in practice by the need
for ongoing interactions with a therapist. Compared to the convenience of a pill that can
be consumed anywhere at any time, maintaining a schedule of visits to the therapist may
be a challenge, especially for individuals with attentional difficulties.
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What is needed then is a method of providing the benefits and lasting effects of
therapy, with the convenience of taking medication. Biofeedback – and more specifically
neurofeedback – may provide the solution. Biofeedback is the process of measuring a
subject’s physiological processes, and visualizing the measurements so that the subject is
aware of the physiological processes. Neurofeedback is a similar process involving
neurological signals and processes instead of physiological signals and processes.
Biofeedback and neurofeedback are relatively new fields having emerged in the last half
century but are already used extensively to treat a variety of ailments both physical and
psychological.
There are a few drawbacks to biofeedback and neurofeedback treatments; the
biggest being transportability of treatment. To accurately measure and analyze brain
signals, a large headset attached to a powerful desktop computer must be used, limiting
the transportability of the system. Furthermore, because data is only collected when a
patient is using a neurofeedback device, they must go to the clinician’s office for repeated
sessions in order to collect sufficient amounts of data. However, a there may now be a
solution.
In the past 5 years, the consumer tech market has witnessed an explosion of
“wearable tech”. Wearable tech is the term used to refer to any portable electronic device
that is worn on the body such as a watch or glasses. These devices come with a variety of
sensors built in with the purpose of measuring bodily functions including heart rate,
blood oxygen levels, activity levels (steps taken, minutes spent exercising, etc.), and
sleep patterns/quality. Currently, wearable tech is used to promote consumer health and a
healthier life style, but the sensors and technology employed is underutilized.
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This poses the question: can wearable tech devices be used as a biofeedback
device for a psychological disorder such as ADHD? The purpose of this thesis is to
critically evaluate the data regarding biofeedback treatments and compare it to
conventional treatments. If biofeedback and neurofeedback are both found to be effective
treatments, then a proposal on how to employ wearable tech for the treatment of ADHD
will be given.

Biofeedback
Biofeedback is the process of measuring a subject’s physiological processes, and
visualizing the measurements so that the subject is aware of the physiological processes
(Durand, Barlow, 2009). Biofeedback relies on physiological recording techniques that
are typically electrical in nature: electromyography, electroencephalography, and
electrocardiography. These methods were originally developed in a clinical setting and
are used to measure various physiological phenomena within the body.
Electromyography (EMG) is used to record the electrical activity produced by
skeletal muscles (Tassinary, 2007). This is achieved by measuring the overall electric
potential generated by cell muscles which, is measurable through a subject’s skin.
Various muscular ailments are treated today using EMG biofeedback. One such ailment
is Spastic Pelvic Floor Syndrome (SPFS). Spastic pelvic floor syndrome (SPFS) is a
functional disorder of the pelvic floor muscle wherein during straining, the muscle
contracts instead of relaxes, causing a functional rectal outlet obstruction (Dickinson,
2006). Prior to EMG biofeedback, SPFS was commonly treated with laxatives and water
enemas. Repeated use of such devices can leave lasting damage internally. The key
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feature of the treatment is that a patient relearns normal, autonomous muscle functioning
(Barnett, 2014).
When a subject’s floor muscle is straining, their EMG measurements read 70+
microvolts; conversely, when a subject’s floor muscle is relaxed, their EMG
measurements read >20 microvolts. While observing his/her EMG measurements in real
time, a patient focuses on the sensation of his/her contracting muscles. Then, the patient
must think about lowering the EMG levels, and focus on the muscle sensation that
follows. As the patient focuses on the EMG read out, his/her muscles will contract or
uncontract accordingly. The EMG read out allows the patient to observe, process, and
control bodily signals that they were unable to process prior. In the case of SPFS, it is
processing and controlling the signals between the brain and pelvic floor muscle.
Furthermore, through repeated sessions, a patient can relearn control of a given muscle
without the aid of an EMG readout, having relearned how to process his/her bodily
signals.
EMG biofeedback is only one of the three major biofeedback recording methods.
Electrocardiography (EKG) and electroencephalography (EEG) are used in a similar
manner when working with the heart and brain respectively. The major impact of
biofeedback is that it is psychological in nature. Biofeedback does not require the use of
medications or special medical procedures; all that is required are non-invasive sensors
placed on the patient’s skin. Starting in 1958 – when Dr. George Mandler proved the
existence of a link between psychological and physiological reactions – hundreds of
studies have proven the efficacy of biofeedback in treating a variety of physiological and
psychological pathologies (Thatcher, 2015).
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In 1865, Claude Bernard proposed the theory of homeostasis. Homeostasis states
the human body will actively regulate bodily functions to maintain a state of constant
being. The theory stated that each bodily function was regulated and controlled by a
biological mechanism known as a homeostat. Bernard proposed that if a person was able
to control a homeostat, they would have voluntary control over the corresponding bodily
function (Bernard, 1957). Twenty years later, Ivan Tarkhanov, a Russian physiologist
most known for his discoveries in the heart and circulatory system, demonstrated that
voluntary control of one’s heart rate was relatively easy through simple concentration on
the sensation of the beating heart (Tarchanoff, 1885). At the time, the discovery remained
little more than a scientific amusement.
The next major step in the establishment of biofeedback as a legitimate field of
study came in 1958. Austrian scientist George Mandler conducted an experiment
regarding autonomic self-perception, the awareness of one’s automatic physiological
responses; i.e. sweating when stressed, crying when sad, hyperventilating when scared.
Mandler was specifically interested in the relationship between the severity of autonomic
reactions to one’s awareness of autonomic reactions (Mandler, 1958). Using a selfassessment questionnaire and an interview, Mandler found 14 subjects (Group A) with
high autonomic reaction scores and 9 subjects (Group B) with low autonomic reaction
scores. Subjects from both groups were then placed in high-anxiety situations – difficult
paper exams, scary movies/images – while their autonomic reactivity was measured via
heart rate, psychogalvanic response, respiration, face temperature, and blood pressure.
Subjects were then asked to self-report their own perceived stress level as well as their
own perceived autonomic response level. Mandler’s results showed there was a positive
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correlation between a subject’s self-reported response levels and their observed response
levels (Mandler, 1958). Furthermore, the results revealed that subjects with a high level
of responsiveness almost always overestimated their stress levels while subjects with a
low level of responsiveness almost always underestimated their stress levels. The results
demonstrated two things. First, the results demonstrated a link between psychological and
physiological reactions. Second, and more importantly, the results suggested that if a
subject could control their autonomic responses, they could control their psychological
responses.
4 years later in 1962, Donald W. Shearn, an American scientist conducted an
experiment to determine if a subject could control their heartrate. Shearn took 46
undergraduate male volunteers and provided each subject with a heartrate monitor. Over
the course of 20, 30 second trials, each subject was asked to attempt to raise their
heartrate without the use of hyperventilation. If the subject didn’t successfully raise their
heartrate they were given a mild shock. Results showed that with each session, the
number of times a subject could raise their heartrate increased (Shearn, 1972).
Furthermore, the results showed that if a subject was given less time before the shock,
they were still able to adapt and rapidly increase their heartrate voluntarily. The results of
this experiment demonstrated that it was possible to control one’s heartrate by simply
watching a heartrate monitor. Furthermore, the results This was the first recorded use of
modern biofeedback.
Despite Shearn’s discovery, his experiment wouldn’t be peer-reviewed until a
decade later in 1972 with the release of the ‘Handbook of Psychophysiology’. The peer
review included a replication of Shearn’s experiment, conducted by Thomas McCanne
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and Curt Sandman (Dawson, 2007). The experiment involved twelve healthy male
volunteers from an undergraduate psychology class. Like Shearn’s study, each subject
was presented with a heartrate monitor. McCanne and Sandman’s experiment focused on
a few methodological concerns.
The first method change was that each subject would be asked to both accelerate
and decelerate their heart rate. McCanne and Sandman were interested in the possibility
of different psychological mechanisms involved in learning how to accelerate and
decelerate one’s heartrate. The second method change was that each subject would go
spend a week conduction sessions instead of a few minutes total. Specifically, each
subject would spend five consecutive days with 10, 30 second sessions each day. The
purpose of this change was to determine if control of autonomic physiological functions
could be learned. The results of the experiment revealed that not only indeed could a
subject control an autonomous function such as their heart rate, it became clear that the
subjects had learned how to accelerate and decelerate their heart rate by the end of the
trial, having learned how to do so throughout the week of tests (Dawson, 2007). A
demonstrated and proven ability to learn physiological and psychological self-control
meant that psychological therapies could be used in lieu of drug-based therapies for
physical ailments.
In 1976, the Biofeedback Society of America was established – know known as
The Association for Applied Psychophysiology and Biofeedback – with the goal, as
stated by the AAPB, is to “promote a new understanding of biofeedback and advance the
methods used in this practice.” Soon thereafter, the AAPB researcher John Basmajian
published Biofeedback: Principles and Practice for Clinicians (Basmajian, 1979). The
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purpose of Dr. Basmajian’s publication was to serve as a central source of knowledge
regarding then-current biofeedback techniques. One particular field of interest was
musculoskeletal manipulation of normally autonomous processes; a form of
electromyographic biofeedback (EMG).
As the medical community’s understanding and acceptance of biofeedback grew,
the understanding and acceptance of neurofeedback grew as well. Neurofeedback, much
like biofeedback, is the attempt to manipulate normally autonomous mental functions
through the observation of physiological brain-wave readings. The primary area of
treatment that neurofeedback is aimed at is psychopathologies. In 1994, the AAPB
established a dedicated research group for brain-wave feedback as well as a dedicated
research group for EMG feedback.
That same year, the EMG group published an experiment focusing on the efficacy
of biofeedback in regards to stress and pain management. The experiment – conducted by
Dennis C. Turk, Hussein S. Zaki, and Thomas E. Rudy – involved 80 subjects suffering
from temporomandibular joint dysfunction (TMD) (Turk, 2002). The 80 subjects were
randomly assigned to one of three groups. The first group (Group A) would receive
traditional oral painkillers and would be asked to rate their pain levels following
treatment. The second group (Group B) would receive a biofeedback-based stress/pain
management treatment. Group B was shown a collection of biofeedback readings
consisting of skin conductance, heart rate, blood pressure, and EMG readings of the jaw
muscle. Subjects in Group B would be asked to focus on lowering the biofeedback
readings while remembering the sensation of the lower pain levels. The third group
(Group C) was a control group and didn’t receive any treatment. The results indicated
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that subjects in Group A experienced higher levels of relief than subjects in Group B
following treatment. This was partially to be expected given that TMD is the
inflammation of the jaw joint. Following the initial experiment, a 6-month follow up was
conducted to determine how the subjects’ pain management has progressed. Subjects in
Group A severely relapsed in pain management, a majority of the subjects still relying on
pain medication. Subjects in Group B, however, showed a marked improvement in their
pain management and comfort. Furthermore, a repeat experiment was conducted where
30 subjects were given both oral painkillers and biofeedback-based treatment. This group
showed better improvement than either Group A or Group B, using pain killers for early
relief and transitioning to psychological methods of pain management (Turk, 2002). The
results of this experiment were important because it was one of the first times that
biofeedback had been used to manage pain rather than a specific muscle function. This
was one of the first large steps towards the validation of meditation and thought therapy
as a useful medical tool for patient pain management.

ADHD & Neurofeedback
ADHD is a psychopathology commonly characterized by general inattentiveness
and/or a lack of impulse control resulting in hyperactive tendencies. The Diagnostic and
Statistical Manual, 5th Edition (DSM-5) categorizes the symptoms of ADHD into two
categories: inattention, and hyperactivity and impulsivity. There are three presentations of
ADHD that can occur based on the symptoms present in an individual; they are as
follows: ADHD-Predominantly Inattentive, ADHD Predominantly HyperactiveImpulsive, and ADHD Combined. The symptoms associated with ADHD can interfere
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with a child’s learning as well as an adult’s productivity in the workplace. For example,
an individual with ADHD-Predominantly Inattentive (such as this author), will often have
trouble holding attention on tasks, won’t seem to listen when spoken to directly, and
often loses things necessary for tasks and activities such as eyeglasses or cell phone. In
contrast, individuals with ADHD Predominantly Hyperactive-Impulsive will often fidget
and squirm when seated, have trouble staying seated for extended periods of time, and
talk excessively or out of turn. In order for an individual to be diagnosed with ADHD, he
or she must not only display 6 or more symptoms, but there must also be clear evidence
that the symptoms present interfere with, or reduce the quality of, social, school, or work
functioning. The symptoms present must also be deemed inappropriate for the age or
developmental level of the individual in question (American Psychiatric Association,
2013).
The exact cause of ADHD is unknown, but there are several risk factors that can
contribute to the development of ADHD. If a blood relative, such as a parent or sibling,
has ADHD or similar psychopathology, an individual will be more likely to develop
ADHD. Maternal drug or alcohol abuse as well as premature birth are both identified risk
factors in the development of ADHD. ADHD shares a co-morbidity with several other
psychopathologies including depression, bipolar disorder, Tourette Syndrome, and
general anxiety disorders (Kessler, 2006). Each of the listed psychopathologies –
including ADHD – can be characterized by a chemical imbalance in the brain; more
specifically, an imbalance of key neurotransmitters (American Psychiatric Association,
2013).
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At the neural level, individuals with ADHD are often described as being in an unaroused state (Bakhshayesh, 2010). Critically, the ADHD brain shows measurably lower
levels of one of two specific neurotransmitters: dopamine or norepinephrine. ADHD
Hyperactive-Impulsive is associated with lower levels of dopamine, which is involved in
the regulation of reward-motivated behavior, emotional responses, and motor control.
Consistent with the role of dopamine in motor control, symptoms associated with ADHD
Hyperactive-Impulsive include constant fidgeting or vocal outbursts (Daly, 2015). Due to
dopamine’s role in reward-motivated behavior, symptoms also include general
impatience and a desire to complete a task using minimal effort, often at the cost of
quality (Barkley, 2015). Lower dopamine levels associated with ADHD HyperactiveImpulsive can also be observed as emotional immaturity. Individuals with ADHD
Hyperactive-Impulsive are often characterized as having difficulty maintaining
relationships both intimate and not (Goldstein, 2000).
ADHD Inattentive is marked by reductions in norepinephrine levels.
Norepinephrine is responsible for promoting vigilance, formation and retrieval of
memory, and focusing attention. Consistent with norepinephrine’s role in vigilance,
symptoms associated with ADHD Inattentive include being easily distracted and
difficulty following through on instructions (Prevatt, 2015). Due to norepinephrine’s role
in memory formation and retrieval, symptoms also include difficulty remembering items
in a short amount of time as well as difficulty remembering items without an external aid
in the form of notes (Prevatt, 2015).
In all three subtypes of ADHD, the imbalance of neurotransmitters means that
neuronal connections are weaker. The weaker connection – and imbalance of
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neurotransmitters – is attributed to overactive neurotransmitter transporters.
Neurotransmitter transporters are proteins found in the cell membrane of a neuron. The
transporters are responsible for moving neurotransmitters across the cell membrane to
change the neuron’s cell potential and in turn trigger an electrical signal: the neuron firing
(American Psychological Association, 2013). The transporters in an individual without
ADHD only move neurotransmitters across the cell membrane when necessary, building
up a ready supply of neurotransmitters ensuring that the action potential can be quickly
triggered. In an individual with ADHD, the transporters are overactive. An overactive
transporter moves neurotransmitters across the cell membrane too frequently which, in
turn deprives the neuron of a neurotransmitter reserve. Specifically, an overactive
transporter will move neurotransmitters outside of the cell, inhibiting the reuptake of
neurotransmitters (Pedraza, 2015). By depriving the neuron of an available supply of
neurotransmitters, more time is required to trigger the action potential, slowing down the
entire signal chain.
This delayed neural firing can manifest itself in different behaviors—again,
depending on the ADHD subtype. In the case of ADHD Hyperactive-Impulsive, a lack of
dopamine and slower firing neurons can appear in a patient, for example, as a delayed
impulse control or inability to wait their turn. A lack of norepinephrine and slower firing
neurons in ADHD Inattentive can appear in a patient, for example, as an inability to
quickly memorize information or propensity to misplace items (Pedraza, 2015).
There are two commonly accepted methods of treatment for ADHD. One is to
increase dopamine and norepinephrine levels in the brain to compensate for the
overactive transporters. The second is to inhibit the transporters so fewer
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neurotransmitters are moving across the cell membrane. Currently, there are two classes
of medications available: stimulants and non-stimulants (American Psychological
Association, 2013). Stimulants and non-stimulants are used to treat both ADHD
Hyperactive Impulsive and ADHD Inattentive; whether simulants or non-stimulants are
used is dictated by the treatment method used. Both types of medications allow a
patient’s neurons to build up a neurotransmitter reserve, ready to be moved across the cell
membrane when necessary (American Psychological Association, 2013). The availability
of neurotransmitter reserves is reflected in reduced neurotransmitter
Standard medications provide a subject’s brain with the means to produce the
needed neurotransmitters which, in turn allows the neurons to fire more rapidly due to the
reduced time required to build up neurotransmitters. By increasing the rate of neuronal
communication, these drugs allow the individual to function “normally”; i.e. no longer
engage in or display disruptive symptoms. However, neuronal communication is
enhanced for only as long as the medications last; once the medication has run its course,
the subject’s brain is no longer able to facilitate improved neuronal connections.
Furthermore, as with any drug, tolerance will build up over time, requiring higher and
higher doses for the medications to remain effective. To combat the need for higher
doses, subjects are often taught certain psychotherapies or coping methods that naturally
facilitate improved neuron communication; methods can include frequent exercise/time
outside, avoiding unhealthy foods, and taking frequent notes. Patients might also engage
in cognitive behavioral therapy (CBT) which trains a patient to identify problematic
behaviors and how to manage said behaviors (Pedraza, 2015).
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Behavioral intervention – or cognitive behavioral therapy (CBT) – helps patients
recognize patterns or problem behavior so that they better manage the identified patterns
(American Psychiatric Association, 2013). Furthermore, parents and teachers will be
given strategies to cope with disruptive behavior as well as address problematic
behavioral habits at home and at school. Per a series of studies conducted by CHADD
and the APA, CBT was found to be effective in both an individual and group setting. In
all but one of the studies, CBT yielded significantly improved behavioral patterns and
habits in the subjects (Pedraza, 2015). When CBT was used to help subjects improve
their behavioral habits and patterns, subjects felt that they were being helped and that
their “normalcy” was being reaffirmed (Gevensleben, 2012). CBT is a broad term and
can be achieved through a variety of settings. A therapist or “life coach” can be
considered a form of CBT as well as meditation and/or yoga.
But why does CBT work? CBT works because the subject is made aware of their
behavioral habits. The subject is effectively trained to realize when he/she is engaging in
a behavioral habit and what must be done in such an event. What makes CBT truly
effective however, is the fact that there is a trained professional with the subject making
them aware of their own habits. Once the subject is on their own, they are less likely to be
aware of their behaviors and furthermore will be more likely to regress in their behavioral
management techniques. Much like medication, the subject is still reliant on treatment to
aid in their behavioral management (Gevensleben, 2012). Unlike a pill, therapists cannot
travel with the subject to aid in correcting behavioral habits. If a therapist cannot travel
with the subject, feedback needs to be provided to the subject via another method.
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Without psychotherapy or medications (or a combination of both), a subject is unable to
facilitate improved neuronal communication.
The aim of neurofeedback is to give subjects the ability to facilitate improved
neuronal communication without the aid of medications or psychotherapy (Lofthouse,
2011). Neurofeedback relies on the principle that a subject’s arousal (attentiveness) is
dependent on the pattern of neural oscillations with the brain. Neural oscillation is
repetitive neural activity within the brain. A single neuron repeatedly activating is said to
be oscillating or displaying oscillatory activity. On a single-neuron scale, the oscillations
appear as oscillations in the membrane potential. At the level of neural ensembles –
groups of neurons activating in synchrony – the synchronized oscillations are measurable
through the scalp using an electroencephalogram (EEG) and appear as signal frequencies,
or brain waves.
There are four well-studied brain wave levels: delta, theta, alpha, beta. Delta
waves range from 0.5 to 3.0 Hz and are present only when a subject is engaged in deep
sleep. Theta waves range from 3.0 to 8.0 Hz and are present during light sleep and when
a subject is awake but inattentive. Alpha waves range from 8.0 to 13 Hz and are present
during any waking moment, and will disappear during moments of attentiveness. Beta
waves range from 13 to 22 Hz and are present when a subject is alert, attentive, or
engaged in various high level mental thoughts (Lofthouse, 2011).
As in biofeedback, a representation of the measured brain signals is shown to the
subject for the purpose of teaching the subject to learn to regulate their brain activity. The
brain signal representation often takes the form of a video game (Monastra, 2008). When
a subject’s brain wave activity indicates arousal and attentiveness – meaning their brain is

17
BIOFEEDBACK & ADHD

producing beta waves – the subject is given positive feedback. With this system, subjects
are not only trained to regulate their brain activity, but are also trained to be more
perceptive of how an attentive brain feels (Schummer, 2013).
However, it remains an open question how well neurofeedback works. Various
clinical studies have been conducted to determine the efficacy of neurofeedback. In any
study regarding ADHD severity, a battery of tests is used. The Test of Variables
Attention (TOVA) is a neuropsychological assessment that measures a subject’s level of
attentiveness while simultaneously screening for ADHD. The test is typically presented
as a simple and repetitive game on a computer. The test is meant to measure a subject’s
response to auditory and visual cues. A high TOVA score is indicative of an alert and
attentive subject while a low TOVA score is indicative of a non-attentive subject
(American Psychiatric Association, 2013).
Another test used to diagnose ADHD – among a variety of learning disabilities –
is the Wechsler Intelligence Scale for Children (WISC). The WISC measures verbal
comprehension, visual spatial skills, fluid reasoning, working memory, and processing
speeds. The test is presented as a combination of verbal exams and paper exams. Along
with the WISC, there is the Wechsler Adult Intelligence Scale (WAIS) (American
Psychiatric Association, 2013). Like the WISC, the WAIS is a diagnostic tool used to
measure intellect and cognitive ability in adults. The WAIS measures the same variables
as the WISC, but uses different prompts that are more suited for adults and older
adolescents.
Another commonly used diagnostic tool is the D2 Test of Attention. The D2 Test
of Attention is a neuropsychological test meant to measure selective and sustained
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attention of a subject. On a piece of paper, a subject must be able to find and highlight
specific letters – usually the letter “d”. The object of interest is placed among distractor
objects that have a similar shape – in the case of the letter “d”, each letter could be
surrounded with “p” or “q” (American Psychiatric Association, 2013).
All the tests discussed have been translated and are used world-wide. Due to the
tests’ common use in diagnosing ADHD, studies involving ADHD and behavioral issues
will use these three tests along with peer interviews to measure the severity or change in
ADHD for any given subject (American Psychiatric Association, 2013).
The results pertaining to ADHD and neurofeedback have all been generally
positive. In a study looking at the efficacy of EEG neurofeedback in training various
ADHD coping strategies, children and adolescents (ages 8-19) participated in a 3-month
long program of intensive neurofeedback training where reward was dependent on
maintaining high beta-wave levels while avoiding theta waves (Lubar et al., 1995).
Following the 3-month program, almost all subjects demonstrated improved TOVA
scores, behavioral ratings, and better WISC-R performance. More importantly, these
improvements were comparable to those of a subject on traditional medications (Lubar et
al., 1995).
A similar study was conducted to compare the efficacy of EEG neurofeedback to
the efficacy of traditional medications; in this case, methylphenidate. 22 children (ages 812) participated in a 3-month long program of intensive neurofeedback training while 12
children (ages 8-12) were given methylphenidate over the same 3-month period (Fuchs et
al., 2003). Following the 3-month program, both groups demonstrated improved d2
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Attention Endurance Test scores and behavioral ratings from parents and teachers. These
results demonstrated that EEG neurofeedback was as effective as medications.
In one study, 100 children and teens with ADHD (ages 6-19) were given a variety
of treatments, including medication, school consultation, and parent counseling
(Monastra, 2002). Half of the children received this regimen while the other half received
this regimen along with EEG neurofeedback training. After a year of treatment, both
groups stopped taking the medication and measurements were taken a week later. TOVA
and behavior scores for children who received neurofeedback were found to be in the
“normal” range, or not indicative of ADHD. The scores for children who did not receive
biofeedback were in the “clinical” range, or indicative of ADHD. Furthermore, children
who did not receive neurofeedback started to exhibit ADHD symptoms just a week after
not taking medication and sooner in some cases (Monastra, 2002). This study
demonstrated that neurofeedback is not only an alternative treatment, but is an additive
treatment in the presence of traditional treatments.
Despite its demonstrated efficacy and success in treating ADHD, neurofeedback
still has flaws, some more glaring than others. While neurofeedback eliminates the need
for medication, a subject won’t necessarily pay any less than before. On average, a single
neurofeedback session costs anywhere from $50 to $125 and in order for neurofeedback
to be effective, a subject must undergo 30 to 40 sessions each lasting 2 hours; these are
all the costs AFTER a subject has seen a psychiatrist and physician (Gevensleben, 2012).
Furthermore, due to the novel nature of neurofeedback, many insurance companies view
neurofeedback as experimental, and will not cover the costs. The bulk of the cost for
neurofeedback treatment is in the time spent at the clinic. Whilst small, portable

20
BIOFEEDBACK & ADHD

consumer brain-reading devices have been on the market for almost a decade now, these
devices have been little more than toys, incapable of getting the accurate measurements
required for neurofeedback treatment. The devices required for neurofeedback treatment
cost upwards of $25,000.
What is needed then is a portable device capable of making accurate, reliable, and
usable measurements. More importantly, a device that is discrete is required. The success
of non-medication-based treatments of ADHD, such as CBT, hinge on the subject feeling
“normal” despite their disorder. Brain-reading devices, both consumer and non-consumer
are large and ungainly by nature; even the latest consumer device, the MUSE, is a wide
headband that covers a large part of the user’s forehead and sides of their head. A subject
feeling such a device will not appear as normal and thus most likely will not feel normal.

Proposed Device
As described above, the development of an effective biofeedback device for
ADHD faces key challenges, including portability, accuracy, and discretion. In this
section, I will review existing devices that have been developed to address these criteria,
as well as assessing the technological capabilities of consumer wearable tech and how
consumer tech could be used as a clinical biofeedback device. Based on this analysis, I
conclude that no currently available device fully meets the needs of the ADHD
population. Instead, I propose that rather than developing a bespoke device, current
consumer wearable tech be repurposed to provide clinical biofeedback through means of
a bespoke app capable to using the technology found in wearable tech.
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In cooperation with several pharmaceutical companies – including Shire, the
makers of Adderall – the APA has designed and validated several biofeedback-based
CBT computer programs. While using the CBT program, the subject’s neurological
processes are recorded using an EEG cap so that the program may provide guidance
accordingly. Much as a therapist would, these programs provide a subject with selfregulation techniques and exercises. Data suggest that CBT computer programs are
successful in treating ADHD (Janessen, 2015). This success stems in part from the fact
that the programming allows the recording device to act on the recorded data. However,
like a therapist, computers capable of running CBT programs are restricted in movement
and typically only exist on desktop systems. Although devices for neurological
monitoring are themselves portable enough for a subject to use on a regular basis and
cost little more than a single drug prescription, these monitoring devices do little else
than record data. Even the most advanced portable recorder produced by the leading
biofeedback device manufacturer (Current Technology Inc., Minneapolis, MN) lacks
programmable logic, the ability to run any sort of on-board data analytics. Therefore,
what is needed is a data recording device capable of data analytics—a portable computer.
To address this issue, several biomedical companies have released apps and proprietary
devices that together can perform a wide variety of tasks. However, on their own, each
device is highly specialized, providing information pertinent to one or few
Thanks to advancements in modern computing, though, most of the population
has access to a portable computer, in the form of a smartphone. Smartphones are
incredibly powerful devices – the iPhone is more powerful than the computer on Apollo
11 – that can be connected to any number of devices. These devices include headsets,

22
BIOFEEDBACK & ADHD

cars, and most importantly, bio recording devices. As smartphones continue to advance, a
new market has emerged which might provide a universal biofeedback device: wearable
tech.
Wearable tech was introduced to the consumer market with the release of the Fit
Bit in 2007. The Fit Bit is marketed as an activity motion tracker capable of counting a
subject’s steps, measuring their heart rate, measuring their blood-oxygen levels, sleep
schedule, and exercises performed (FitBit, 2016). Furthermore, the device acts as a
communication device for the phone, allowing a user to talk on the phone and reply to
texts without needing to directly access the smartphone. The Fit Bit device itself is worn
on the subject’s wrist and is smaller and lighter than most watches. Since the introduction
of the original Fit Bit, the wearable tech market has grown to a nearly $14 billion
industry with 60 million devices being sold each year (Statista, 2016). Major consumer
electronics companies including Apple and Samsung have entered the market with wellknown devices such as the Apple Watch and Samsung Gear. Thus, wearable tech devices
have the benefit of already being a popular technology, eliminating the need to create
bespoke sensors and devices.
However, despite the popularity of wearable tech, their location on the body (e.g.,
wrist) limits their capabilities to motion tracking and blood flow monitoring. Although
head-mounted technologies such as virtual reality are receiving new attention (Statista,
2016), to date no neurological recording device has been designed for discreet, portable
day-to-day wear. This means that for a wearable-tech device to be successful, it must be
possible to monitor a psychological disorder using these types of physiological
measurements.
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In the case of ADHD, existing technologies have instead focused on directing the
user’s attention towards specific reminders and tasks. Currently, there are a number of
wearable devices on the market that are designed to aid in directing a user’s focus,
including the WatchMinder and T.Jacket. The WatchMinder (WatchMinder, 2016) is a
small watch-life device that allows a user to create discreet cues throughout the day that
remind them to perform specific tasks. These tasks are determined by the user, but
examples include a child receiving notifications of when to take medications, or an adult
being reminded of an upcoming meeting at work. Similar functionality is provided by
other wristband devices such as the Re-vibe and Sqord (FokusLabs, 2016) (Sqord, 2016).
Another similar device is the T.Jacket. Similar to the WatchMinder, the T.Jacket
provides discrete reminders to the user to perform certain tasks. However, unlike the
WatchMinder, the T.Jacket (as the name implies) is a jacket-like piece of clothing that the
user wears. The reminders are delivered via pressure applied by the jacket (imagine a
hug) and can be remotely delivered by a parent or caretaker if necessary (TWare, 2016).
Despite their prevalence on the market, these devices suffer from major flaws,
including requiring user input, being subject to habituation, and lacking awareness of the
user’s physiological state. First, the current offering of devices requires that the user set
up reminders, which limits the functionality to dealing with events or tasks that are
already scheduled. Furthermore, because most of these devices don’t have a screen, they
rely on the user to remember what the task in question is. When dealing with
psychopathologies that affect memory, such as ADHD, this can lead to obvious
problems. Worse, most current smartphones already come with reminder systems that
have equal or greater capability. For example, both the iPhone and Samsung Galaxy can
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deliver reminders based on a variety of conditions beyond time – location, whom the user
is talking to, current activities – as well as delivering reminders just as discreetly.
This style of schedule or task reminder also suffers from habituation. As with
medications, it is possible for users to build a “tolerance” to the reminders, especially if
they are time-based (Thatcher, 2015). Over time, the user will learn to anticipate the
reminders, and depending on the task, could begin to intentionally ignore the reminder.
This is especially the case when children must take medications at specific times
(Schummer, 2013). Furthermore, none of the current devices can deliver “context
dependent” reminders. A context dependent event is an event that will only occur when
certain criteria are met. In terms of reminders and scheduling, a context dependent
reminder is a reminder that will only appear when necessary. For example, a child that
needs to take medications at a specific time while at school won’t want to receive
reminders while on vacation or during the weekend when taking medications isn’t
necessary.
It is important to note that reminders are not detrimental or useless to those with
ADHD; quite the opposite in fact (Salomone, 2012). However, reminders do not serve a
therapeutic purpose. Reminders are simply another tool for those ADHD to rely on, and
do not aid in the memory formation or recall necessary to remember tasks and
instructions. What is required is a therapeutic device that responds not simply to time or
location, but also responds to the current task at hand and most importantly, the current
focus level of the user. As stated earlier, the device I am proposing wouldn’t be able to
measure brain activity; it must rely on physiological measurements representative of the
user’s attentiveness.
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Current wearable tech can detect what type of motion or exercise a user is
performing based on the measured wrist motions and accelerations. Furthermore,
wearable tech – using the same methods – can determine a user’s body position or stance
and provide feedback accordingly. It stands to reason that this technology could be
repurposed to detect when a user is attentive or inattentive. Studies conducted in the last
year suggest that there is indeed a body position associated with attentiveness and a body
position associated with inattentiveness; most importantly, the body positions are
measurably different from each other. However, the specific details of the body positions
are still debated.
One study involving 110 adolescents (13 – 17 years old) with ADHD Combined
measured each subject’s body position and movements during times that required focus
(Cheung et al., 2016). Data was collected over the course of six years. The study revealed
that subjects who were focused would almost always engage in a “preparation-vigilance
measure”. A preparation-vigilance measure, per the study, was a biomarker that was
closely correlated with higher levels of attention. In this case, the preparation-vigilance
process varied from subject to subject, but followed a similar pattern: prior to focusing,
the subject would engage in a pattern of deep breathing, shaking out their arms, or a
closing their eyes for a moment. Subjects who didn’t engage in a similar activity almost
always exhibited lower levels of attentiveness and awareness. Results also suggested that
subjects who continued to engage in preparation-vigilance processes were more likely to
experience a remission in their ADHD and associated symptoms (Cheung et al., 2016).
Deep breathing and shaking of the arms can both be detected using current market
technology. The breathing could be detected via a sudden change in heart rate and blood
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oxygen levels using a heart rate monitor, whereas shaking of the arms could be detected
via gyroscopes and accelerometers. Both of these technologies are already found in
wearable tech products. By measuring and identifying these physiological markers of
focus, a context dependent device could be developed that knows when it is time to
focus, and it is not. However, this is only useful if the device is also capable of keeping a
user focused; in other words, knows when the user loses focus.
Evidence from research suggests that in patients with ADHD, decreased motion is
associated with worse executive function. A study involving 29 children with ADHD
Hyperactive Impulsive and 23 children without ADHD (8 – 12 years old) compared
subjects’ activity level to their working memory performance (Sarver et al., 2015). Each
subject performed four different working memory exercises while their physical activity
levels were monitored and recorded. Results revealed that working memory performance
was measurably improved during high rates of physical activity in subjects with ADHD.
Conversely, subjects without ADHD had higher working memory performance during
lower rates of physical activity. Further research must be (and is currently being)
conducted to determine why those ADHD rely on physical motion; but this study
provided more evidence for physiological detection of focus. Similar to how they detect
exercises, wearable tech could monitor the physical motions associated with working
memory functions, and detect when a user’s working memory is underperforming.
Another measurable physiological factor associated with ADHD is sleep
disruption. Studies suggest that the severity of ADHD symptoms are determined by how
well rested a subject is (Gaultney, 2005). For example, one study recorded the sleep
patterns of 283 subjects with ADHD (birth – 18+ years old) and compared the sleep
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patterns to reported behaviors. The results suggested a strong correlation between poor
sleep and an increase in negative behaviors (impulsive acts, resistance to authority, lower
cognitive performance). After controlling for age, the correlation was still present. This
study suggests that sleep can determine how focused or not focused a subject will be
throughout the day. This is information that can be used by a context-aware device.
Current wearable tech devices – and smartphones in general – have built in sleep
measuring capabilities that detect a user’s movement, body position, and noise levels
during sleep.
Based on these measurements, a device can determine approximately which stage
of sleep a user is in at any given moment. This ability to determine a user’s quality of
sleep lends itself towards creating a context-aware device. For example, if the device has
information that a user with ADHD slept poorly in the previous night, it could be
programmed to provide more frequent feedback or monitoring to compensate for poor
sleep.
Above all else, however, wearable tech is discrete. Unlike neurofeedback devices
such as the MUSE, wearable tech is no less discrete than a wrist watch or pair of glasses.
The size and convenience of wearable tech have been the primary drivers of the
popularity of wearable tech. This rise in popularity means that as time goes on, everyone
– regardless of mental health – will have a wearable device of some form, further
decreasing the stigma that might have existed from wearing biofeedback-specific devices.
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Conclusion
Using wearable tech, it is possible to create a biofeedback device capable of
providing real time feedback therapy for a user with ADHD. This would most likely be
achieved through the development of a bespoke algorithm – or app – that measures and
responds to the various biological readings provided by the device. Some companies have
already begun to develop apps that provide neurofeedback. One such example is FOQUS
(Foqus Labs, 2016).
FOQUS is an experimental app that aims to address the mental health issues of
ADHD. FOQUS does so by providing a patient with text based alerts, time management
techniques, and guided meditation. Initial testing of the app revealed that the app was
successful in reducing users’ anxiety as well as improving their overall organization
skills. However, FOQUS is still not a true biofeedback device. The next step in
development would be to develop an algorithm that responds in real time to physical
cues. FOQUS is still currently time based, and runs on a predetermined schedule. For
example, rather than having a pre-set meditation period, the app would measure heart rate
and movement, and if the user’s heart rate or movement is beyond normal parameters, the
app would prompt the user to take a break or meditate. Similarly, if the app were able to
detect overly long periods of stillness, it might prompt the user with a reminder.
In conclusion, the technology to develop a biofeedback device for ADHD is
already on the market – and will only continue to improve. However, the efficacy of
biofeedback in treating ADHD will only be as great as the applications developed for
consumer tech. As wearable tech continues to improve, more and more apps will be
released, ushering in a new area of affordable, long lasting, and personalized medicine.
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